<DOC>
	<DOCNO>NCT01652729</DOCNO>
	<brief_summary>To compare effect glycemic control ( HbA1c ) exenatide suspension administer weekly achieve sitagliptin placebo administer daily 28 week subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>Comparison Study Glycemic Effects , Safety , Tolerability Exenatide Once Weekly Suspension Sitagliptin Placebo Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>At least 18 year old Diagnosed type 2 diabetes mellitus HbA1c 7.1 % 11.0 % , inclusive , screen Has stable body weight , i.e. , vary &gt; 3 % least 3 month prior screen Fasting plasma glucose concentration &lt; 280 mg/dL ( 15.5 mmol/L ) screen Body mass index &lt; 45 kg/m2 screening Has treat stable regimen ≥1500 mg/day metformin minimum 2 month prior Visit 1 ( Screening ) History pancreatitis triglyceride &gt; =500 mg/dL Medullary carcinoma multiple endocrine neoplasia ( MEN2 ) family history either History renal transplantation , currently receive renal dialysis , estimate creatinine clearance &lt; 50 mL/min Active cardiovascular disease Presence history severe congestive heart failure Central nervous system disease , include epilepsy Liver disease History severe gastrointestinal disease Clinically significant malignant disease Repeated severe hypoglycemia within last 6 month Any exposure exenatide ( BYETTA® BYDUREON™ ) GLP1 analog Any DPP4 inhibitor within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Diabetes , Type 2 , exenatide , Sitagliptin</keyword>
</DOC>